cardiorenalmetabolic

Patients

The podcast welcomes Dr Ramy Younes, corporate VP, global head of clinical development, cardiorenalmetabolism, at Boehringer Ingelheim.

News

Johnson & Johnson has built its presence in KRAS drugs for cancer with a $1bn deal to buy Firefly Bio and its degrader-antibody conjugate platform.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.